Cerus-backed Opocrin completed the acquisition of Laboratori Derivati Organici.

Boutique office management firm Cerus Advisors-backed Opocrin, a global manufacturer of active pharmaceutical ingredients, completed the acquisition of Laboratori Derivati Organici, a pharmaceutical company. Financial terms were not disclosed. "Cerus Advisors has dedicated significant time and resources to the development of LDO over the last 9 years and this transaction represents the culmination of these efforts. We are also pleased with the creation of a group that has significant potential for continued value creation for its shareholders," Marios Fotiadis, Cerus Chairman, Manager Partner.